Silymarin (Milk Thistle) Treatment of Adults With Gambling Disorder: A Double-Blind, Placebo-Controlled Trial.

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY

Clinical Neuropharmacology Pub Date : 2024-03-01 DOI:10.1097/WNF.0000000000000585

Jon E Grant, Corine Driessens, Samuel R Chamberlain

{"title":"Silymarin (Milk Thistle) Treatment of Adults With Gambling Disorder: A Double-Blind, Placebo-Controlled Trial.","authors":"Jon E Grant, Corine Driessens, Samuel R Chamberlain","doi":"10.1097/WNF.0000000000000585","DOIUrl":null,"url":null,"abstract":"Objective: Data on the pharmacological treatment of gambling disorder are limited. Silymarin (derived from milk thistle) has antioxidant properties. The goal of the current study was to determine the efficacy and tolerability of silymarin in adults with gambling disorder.Methods: Forty-three individuals (18 [41.9%] women; mean age=49.61 [±13.1] years) with gambling disorder entered an 8-week, double-blind, placebo-controlled study. Dosing of silymarin ranged from 150 to 300 mg twice a day. The primary outcome measure was the Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS). Secondary outcome measures comprised the Gambling Symptom Assessment Scale and measures of depression and anxiety. Outcomes were examined using mixed-effect models.Results: Silymarin did not statistically differentiate from the placebo on any of the outcome measures of interest, in terms of treatment group×time interactions. There was a robust response in the placebo group (57% reduction on the PG-YBOCS), and on average there was a 56% reduction in YBOCS score for the milk thistle.Conclusions: The findings of this study do not support the use of silymarin/milk thistle in the treatment of gambling disorder but highlight the large placebo response seen in gambling disorder. Treatment interventions for gambling disorder need to better understand and address the placebo response.Trial registration: ClinicalTrials.gov identifier: NCT02337634.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"47 2","pages":"54-58"},"PeriodicalIF":0.8000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000585","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Data on the pharmacological treatment of gambling disorder are limited. Silymarin (derived from milk thistle) has antioxidant properties. The goal of the current study was to determine the efficacy and tolerability of silymarin in adults with gambling disorder.

Methods: Forty-three individuals (18 [41.9%] women; mean age=49.61 [±13.1] years) with gambling disorder entered an 8-week, double-blind, placebo-controlled study. Dosing of silymarin ranged from 150 to 300 mg twice a day. The primary outcome measure was the Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS). Secondary outcome measures comprised the Gambling Symptom Assessment Scale and measures of depression and anxiety. Outcomes were examined using mixed-effect models.

Results: Silymarin did not statistically differentiate from the placebo on any of the outcome measures of interest, in terms of treatment group×time interactions. There was a robust response in the placebo group (57% reduction on the PG-YBOCS), and on average there was a 56% reduction in YBOCS score for the milk thistle.

Conclusions: The findings of this study do not support the use of silymarin/milk thistle in the treatment of gambling disorder but highlight the large placebo response seen in gambling disorder. Treatment interventions for gambling disorder need to better understand and address the placebo response.

Trial registration: ClinicalTrials.gov identifier: NCT02337634.

查看原文本刊更多论文

水飞蓟素（水飞蓟）治疗成人赌博障碍：双盲、安慰剂对照试验。

目的：有关药物治疗赌博障碍的数据十分有限。水飞蓟素（源自奶蓟草）具有抗氧化特性。本研究旨在确定水飞蓟素对成人赌博障碍患者的疗效和耐受性：43名赌博障碍患者（18 [41.9%]名女性；平均年龄=49.61 [±13.1] 岁）参加了为期8周的双盲安慰剂对照研究。水飞蓟素的剂量从 150 毫克到 300 毫克不等，每天两次。主要结果测量指标是耶鲁布朗病态赌博强迫量表（PG-YBOCS）。次要结果测量包括赌博症状评估量表以及抑郁和焦虑测量。结果采用混合效应模型进行检验：就治疗组×时间交互作用而言，水飞蓟素与安慰剂在任何相关结果指标上都没有统计学差异。安慰剂组的反应强烈（PG-YBOCS得分降低了57%），而奶蓟草的YBOCS得分平均降低了56%：本研究结果不支持使用水飞蓟素/水飞蓟治疗赌博障碍，但强调了在赌博障碍中出现的大量安慰剂反应。赌博障碍的治疗干预措施需要更好地理解和应对安慰剂反应：试验注册：ClinicalTrials.gov identifier：NCT02337634。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.